PDF(Pubmed)
Abstract：
Human epidermal receptor (HER) 2-positive advanced gastric cancer is one of the major subtypes of gastric cancer, accounting for ~20% of all cases. Although combination therapy with trastuzumab and chemotherapy provides meaningful survival benefit, clinical trials targeting HER2 have failed to demonstrate clinical benefits in first- or subsequent-line treatment. Trastuzumab deruxtecan, an antibody-drug conjugate, has shown positive results even in later-line treatment and has become new standard treatment. In first-line therapy, combination therapy with pembrolizumab and trastuzumab plus chemotherapy demonstrated a dramatic response rate. Therefore, the FDA rapidly approved it without waiting for the results of survival time. The emergence of combination therapy including immunotherapy with HER2-targeting agents and the development of HER2 targeting agents with or without immunotherapy have been advancing for treating HER2-positive gastric cancer. In this review, we will discuss the current status of treatment development and future perspectives for HER2-positive gastric cancer.
摘要：
人表皮受体(HER)2阳性晚期胃癌是胃癌的主要亚型之一,约占所有病例的20%。尽管曲妥珠单抗和化疗的联合治疗提供了有意义的生存益处，针对HER2的临床试验未能证明一线或后续一线治疗的临床获益.曲妥珠单抗deruxtecan,抗体-药物偶联物,即使在后期治疗中也显示出积极的结果，并已成为新的标准治疗方法。在一线治疗中，派姆单抗和曲妥珠单抗联合化疗的联合治疗显示出显著的缓解率.因此,FDA迅速批准了它，而无需等待生存时间的结果。包括使用HER2靶向剂的免疫疗法的联合疗法的出现以及使用或不使用免疫疗法的HER2靶向剂的开发已经在治疗HER2阳性胃癌方面取得了进展。在这次审查中,我们将讨论HER2阳性胃癌的治疗发展现状和未来前景.
